New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
05:48 EDTPSTIPluristem's manufacturing facility approved by EU auditors for Phase III trials
Pluristem Therapeutics announced that its new manufacturing facility has received the European Union's Qualified Person Declaration. With this declaration, Pluristem is now approved to use cell therapies manufactured at its state-of-the-art facility located in Haifa, Israel, in all phases of its clinical trials conducted in the European Union, including Phase I, Phase II and Phase III. The Qualified Person inspection was conducted in line with the European Union's Good Manufacturing Practice, or GMP, legislation, directives and guidelines. The audit focused on the design, construction and validation of Pluristem's new facility, equipment, utilities, and quality management systems. Pluristem's manufacturing and cell expansion operations were deemed compliant with EU GMP requirements.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:16 EDTPSTIPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
March 24, 2015
09:22 EDTPSTIOn The Fly: Pre-market Movers
Subscribe for More Information
05:29 EDTPSTIPluristem announces strategic objectives for PLX-R18 development
Subscribe for More Information
05:28 EDTPSTIPluristem announces key strategic objectives for PLX-R18 development
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use